VitrenASE Uses, Dosage, Side Effects and more
VitrenASE was developed by ItherX Pharmaceuticals of San Diego. In preclinical studies, companyl has shown that VitrenASE inhibits the growth of cells taken from multiple keloid biopsies as compared to the same keloidal cells treated with a control. It is believed that similar effects would be seen in cells isolated from hypertrophic scars.
| Attribute | Details |
|---|---|
| Trade Name | VitrenASE |
| Generic | VIT-100 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in diabetic retinopathy, scar tissue, and vitreous hemorrhage.
How VitrenASE works
VitrenASE is used for Proliferative Vitreoretinopathy (PVR), a serious eye disease characterized by uncontrolled cellular growth that can lead to retinal detachment and ensuing vision loss. It is expected to reduce the incidence of repeat retinal detachment in patients who undergo surgical repair.
